Estybon (rigosertib) - Traws Pharma, SymBio Pharma, Knight Therap
pevonedistat (MLN4924) - Takeda
sabatolimab (MBG453) - Novartis
Rytelo (imetelstat) - Geron
Tecentriq (atezolizumab) - Roche
Tibsovo (ivosidenib) - Servier
azacitidine - Generic mfg.
Idhifa (enasidenib) - BMS, Servier
emavusertib (CA-4948) - Curis, Dr. Reddy’s
Keytruda (pembrolizumab) - Merck (MSD)
Rezlidhia (olutasidenib) - Rigel
elritercept (KER-050) - Takeda
https://library.ehaweb.org/eha/2025/eha2025-congress/4161848/moazzam.shahzad.efficacy.and.outcomes.of.novel.therapeutic.agents.as.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31565%2Amarker%3D5845%2Afeatured%3D19595
 
Moazzam Shahzad; Hafiz Javed; Muhammad Fareed Khalid; Aniqa Faraz; Abat Khan; Zeeshan Sattar; Maheen Zahid; Ramiro Garzon; Zaker Schwabkey
 
May 16, 2025
 
Prev Next